1 abbvie, inc. date: 12 november 2013 jing chen hisham haider dewan harout sahakian
TRANSCRIPT
![Page 1: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/1.jpg)
1
AbbVie, Inc.Date: 12 November 2013
Jing ChenHisham Haider Dewan
Harout Sahakian
Jing ChenHisham Haider Dewan
Harout Sahakian
![Page 2: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/2.jpg)
Agenda
2
• Introduction• Holding information• Macro-economic overview• Industry analysis• Company overview• Financial analysis and projections• Valuation• Recommendation
![Page 3: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/3.jpg)
Introduction to AbbVie, Inc.
3Source: AbbVie Inc. 10K Filing 2012, Page 1, 6, 13
![Page 4: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/4.jpg)
Business Segments
•Metabolics/Hormones• Virology• Endocrinology• Dyslipidemia• Other
4Source: AbbVie Inc. 10K Filing 2012, Page 1-3
![Page 5: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/5.jpg)
Products and Revenue in Q1-Q3 FY 2013
• HUMIRA: $7,620 mil. • Metabolics/Hormones products: Synthroid, AndroGel, Creon $1,476m• Virology products: Kaletra, Norvir, $816m• Endocrinology products: Lupron, $576m• Dyslipidemia products: TriCor and TRILIPIX, Niaspan, $893m• Other products: Synagis, Anesthesia product Sevoflurane, Duodopa
and Duopa, Zemplar, $1,259m• 20 products in pipeline
5Source: Bloomberg Terminal, Revenue by product
![Page 6: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/6.jpg)
Revenue Breakdown by Major Drugs
6Source: AbbVie, Inc. 2012 10K filing page 45
![Page 7: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/7.jpg)
Where Does AbbVie Sell?
7Source: AbbVie, Inc. 2012 10K filing page 45
![Page 8: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/8.jpg)
Revenue by Product
8Source: AbbVie, Inc. 2012 10K filing page 45
![Page 9: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/9.jpg)
Patent of HUMIRA
• HUMIRA entitled to 12 years exclusivity under the Biologics Price Competition and Innovation Act
• EU has created a pathway for approval of biosimilars• In the US patent for Humira is expected to expire in December
2016, and the EU patent is expected to expire in the majority of EU countries in April 2018
9Source: AbbVie, Inc. 10K 2012 page 5
![Page 10: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/10.jpg)
R&D Process and Patents
10
AbbVie R&D Expense $2.8B in FY2012
Source: AbbVie, Inc. 10K 2012 page 3 and 4
![Page 11: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/11.jpg)
Distribution and MarketingDistributors•McKesson – 38%•Cardinal Health – 27%•AmerisourceBergen – 26%Three largest distribute 91%
Distributors•McKesson – 38%•Cardinal Health – 27%•AmerisourceBergen – 26%Three largest distribute 91%
11
Target market•Physicians•Health Care Providers•Hospitals•Government Agencies
Target market•Physicians•Health Care Providers•Hospitals•Government Agencies
Source: AbbVie, Inc. 10K 2012 page 6
![Page 12: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/12.jpg)
Current Holdings
400 shares•200 shares @ $27.08•100 shares @ 27.53•100 shares @ 34.22
Total Purchase Price (adjusted for split) = $11,591Current Market Value = $19,428Holding period return (from Jan 02, 2013 to Nov 11, 2013) = 67.61%
12Source: Yahoo Finance
![Page 13: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/13.jpg)
Macro-economic Overview
• Slowing growth in BRICS countries• Increasing number of physician visits1
• Adults aged 65 and over 13.7% of US population & rising• High birth rates in emerging markets• Increasing socio-economic status in emerging markets• Increasing emphasis on disease prevention• Changing regulatory environment
13Source: 1. IBISWorld Industry Report 33451b Medical Device Manufacturing in the US October 2013, page 42. US Census Bureau http://quickfacts.census.gov/qfd/states/00000.html
![Page 14: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/14.jpg)
Brand Name Pharma. Industry in U.S.
14Source: http://clients1.ibisworld.com/reports/us/industry/ataglance.aspx?entid=487 Brand Name Pharmaceutical Manufacturing in the US industry report Page 4
![Page 15: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/15.jpg)
Pharma. Industry In The U.S.
• U.S. spending on prescription medicine down 1% in 2012 – first decline since 1957
• Spending on name brand drugs in the U.S. declined 4.7% in 2012
• Market share of generic drugs accounted for 84% of dispensed prescriptions – 5 years ago the share was only 69%
• Reasons for decline include lower volume growth, loss of patent protection on major drugs, and less spending on new drugs
15Source: Mergent. North America Pharmaceuticals Sector. July 2013. Pg 9.
![Page 16: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/16.jpg)
Where’s the Growth Opportunity?
• Emerging Markets - By 2018, global drug makers expect emerging markets to account
for more than 33% of company sales• FDA Approvals - In 2012, the FDA approved 39 new medicines – the highest in 15
years• Hepatitis C- Affects 150 million people worldwide- 10 drugs in development for treating disease
16Source: Mergent. North America Pharmaceuticals Sector. July 2013. Pg 15-16.
![Page 17: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/17.jpg)
Patient Protection & Affordable Care Act: Impact on ABBV
• Healthcare coverage available to all Americans
• An attempt to keep costs lows• Changes how care is paid for• Annual Fee on branded
prescription pharmaceutical manufacturers and importers
17Source: IRS website http://www.irs.gov/uac/Affordable-Care-Act-Tax-Provisions
![Page 18: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/18.jpg)
Risks to AbbVie
18
![Page 19: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/19.jpg)
Porter's Five Forces Analysis for ABBV
19
![Page 20: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/20.jpg)
SWOT Analysis for AbbVie
20
![Page 21: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/21.jpg)
AbbVie Life Cycle
21Source: http://marygardiner.wordpress.com/2013/05/28/product-cycles/
![Page 22: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/22.jpg)
Recent Financial Performance• Humira sales grew 22.3% in U.S. Q3 FY2013• TriCor/Trilipix sales decline due to the loss of exclusivity• R&D was 15.2% of sales in 3Q, reflecting growing need to fund mid
and late-stage pipeline asset• Expects to commercialize HCV by 2015
22
Source: ABBV 8K filed on 2013-10-25, ABBV CFO presentation in JP Morgan Healthcare Conference http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTY2OTgyfENoaWxkSUQ9LTF8VHlwZT0z&t=1
![Page 23: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/23.jpg)
Equity Performance
23
Source: Google Finance Jan 2, 2013 to Nov 11, 2013
![Page 24: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/24.jpg)
Technical Analysis
24
Source: Google Finance Feb 5, 2013 to Nov 11, 2013
![Page 25: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/25.jpg)
Quarterly Ratio Analysis
25
Profitability Q1 FY 2013 Q2 FY 2013 Q3 FY 2013 Return on Assets % 12.1% 13.8% 13.82%#
LiquidityQ1 FY 2013 Q2 FY 2013 Q3 FY 2013
Current Ratio 2.2x 2.3x NA Quick Ratio 1.7x 1.8x NA
Source: Capital IQ Ratios based on quarterly data; #based on end of Q2 FY 2013 Total Assets; *Assumes book value of debt and equity
Solvency Q1 FY 2013 Q2 FY 2013 Q3 FY 2013 Total Debt/Equity* 512.6% 425.9% LT Debt/Equity* 497.9% 413.8% Total Liabilities/Total Assets* 89.1% 87.3% EBIT / Interest Exp. 18.3x 19.3x 24.0x
![Page 26: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/26.jpg)
26
Valuation Valuation
![Page 27: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/27.jpg)
Cost of Capital
27
Cost of equity using CAPM 9.74%
Weighted average cost of debt 2.40%
Cost of equity using goal post method (CAPM Re + 1.85% ) 11.59%
Market value of debt $Mil. * 14,758
Market value of equity $Mil. * 76,148.1
Weight of debt* 16.23%
Weight of equity* 83.77%
Tax rate 22.00%
Number of shares outstanding 1,577
WACC 10.01%
Cost of equity using CAPM
Beta 1.18Market risk premium (Rm-Rf) 6.00%
10 year treasury yeild 2.66%Cost of equity using CAPM 9.74%
* Assumes market value of debt & equity instead of book value on the balance sheet
![Page 28: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/28.jpg)
Free Cash Flow to Firm 2013 2014 2015 2016 2017 2018EBIT $6,217.04 $6,465.72 $6,724.35 $6,993.32 $7,273.05 $7,563.97 Taxes $1,295.99 $1,361.94 $1,422.31 $1,485.10 $1,550.33 $1,588.57 Plus: Depreciation & Amortization $1,190.11 $1,152.98 $1,101.13 $1,043.29 $1,043.29 $1,043.29 Less: Capital Expenditures + Acquisitions ($1,083.27) ($1,126.60) ($1,171.67) ($1,218.53) ($1,267.27) ($1,317.97)Less: Change in Net Working Capital ($7.00) $358.70 ($200.83) ($187.29) ($194.78) ($202.57)Free Cash Flow to Firm $5,034.88 $4,771.45 $5,432.33 $5,520.26 $5,693.51 $5,903.30
28
![Page 29: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/29.jpg)
Discounted Cash Flow
WACC 10.0118%% Growth Rate 4.00%Implied Enterprise Value $88,933.79 Less: Debt $14,758.00 Value of equity $74,175.79 Shares Outstanding 1,577.00 Estimated price per share $47.04
29
![Page 30: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/30.jpg)
DCF – Sensitivity to WACC and G
30
Growth rate
![Page 31: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/31.jpg)
Scenario Analysis (based on revenue)Best case 2013 2014 2015 2016 2017 2018Hepatitis C Virus Franchise 0 0 800 1,200 1,700 2000Daclizumab (Multiple Sclerosi) 0 0 0 100 175 200Revenue boost from pipeline 0 0 800 1,300 1,875 2,200
31
Base case 2013 2014 2015 2016 2017 2018Hepatitis C Virus Franchise 0 0 0 800 1,200 1700Daclizumab (Multiple Sclerosi) 0 0 0 0 100 175Revenue boost from pipeline 0 0 0 800 1,300 1,875
Estimated share price (Best case) $51.77
Estimated share price (Base case) $51.21
Estimated share price (Worst case) $47.04
![Page 32: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/32.jpg)
Comparable Companies to AbbVieCompany Name Market
Capitalization ($Mil) Total Revenue ($Mil)
Actavis plc (NYSE:ACT) 27,278.5 7,648.5 Amgen Inc. (NasdaqGS:AMGN) 85,374.6 18,086.0 AstraZeneca PLC (LSE:AZN) 65,698.2 26,149.0 Bristol-Myers Squibb Company (NYSE:BMY) 86,196.5 16,135.0 Eli Lilly and Company (NYSE:LLY) 55,371.1 23,261.7 Johnson & Johnson (NYSE:JNJ) 265,356.3 70,515.0 Merck & Co. Inc. (NYSE:MRK) 136,746.3 44,450.0 Mylan, Inc. (NasdaqGS:MYL) 15,471.3 6,823.5 Pfizer Inc. (NYSE:PFE) 207,347.8 56,246.0 Teva Pharmaceutical Industries Limited (NYSE:TEVA) 31,493.2 20,133.0 AbbVie Inc. (NYSE:ABBV) 76,148.1 18,885.0
32
![Page 33: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/33.jpg)
Comparable analysis
Comparable ratio Multiple WeightImplied price
per shareTEV/Total Revenues 3.6x 5.0% $36.71 TEV/EBITDA 11.5x 10.0% $47.84 TEV/EBIT 16.6x 15.0% $59.15 TEV/Forward Total Revenue (Capital IQ) 3.4x 5.0% $36.49 TEV/Forward EBITDA (Capital IQ) 10.1x 10.0% $42.72 Market Cap/Total Revenues 3.3x 10.0% $39.42 P/Diluted EPS Before Extra 22.4x 15.0% $65.30 Market Cap / Forward Total Revenues (Capital IQ) 3.2x 5.0% $39.38 Forward P/E (Capital IQ) 14.6x 25.0% $44.77 P/BV 3.7x 0.0% $8.35 Implied price using comparable company data 100% $48.49
33
![Page 34: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/34.jpg)
Valuation using Benjamin Graham's formula
Earnings from 2013 $4,594.87
Expected Annual growth rate G 4.00
Value of equity (E*8.5+2*G) 75815.39
Implied price per share $48.08
34
![Page 35: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/35.jpg)
Key decision driverUpside•Strong presence and growth of Humira•Potential breakthrough in hepatitis C therapy and 20 products in pipeline•Skilled management capable of delivering groundbreaking therapyDownside•Failure to deliver new products or getting regulatory approval•Sales dependent heavily on Humira & limited diversity of products•Product recalls, litigation, high tax burden•Changing regulatory requirements 35
![Page 36: 1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian](https://reader036.vdocuments.us/reader036/viewer/2022062407/56649daf5503460f94a9d700/html5/thumbnails/36.jpg)
Recommendation
Current price/share: $48.57 (Nov 11, 2013)DCF $47.04 DCF Scenario: Best case $51.77, Base case $51.21Comparable $48.49Ben Graham $48.08
36
HOLDHOLD